Overactive bladder treatment includes
various therapies used to treat the sudden, involuntary contraction of
the muscle in the urinary bladder wall. This contraction leads to
urgency to urinate, risen frequency of urinating, nocturia, and
urge-incontinence. Overactive bladder treatment involves several
approaches ranging from medication to behavioral changes as well as a
combination of both medication and behavioral changes. Bladder training
and pelvic floor exercises are natural treatments for overactive
bladder. On the other hand, a group of drugs called anticholinergics
helps to combat the overactive bladder issue by blocking the nerve
signals related to bladder muscle contraction. Rise in research and
development of drugs by key players increases bladder capacity activity.
This, in turn, augments the demand for drugs for use in overactive
bladder treatment. Moreover, new advancements in the analytical method
and the urology diagnostic technique are paving the way for early
diagnosis and treatment of kidney diseases.
High prevalence of diseases such as
chronic kidney disease (CKD) and diabetes, rise in geriatric population,
and increase in research and development initiatives are expected to
drive the global overactive bladder treatment market during the forecast
period. Furthermore, introduction of new constituents of exogenous
markers, rise in government funding, increase in the number of favorable
initiatives for clinical laboratories, development of innovative
intravesical therapies, and aggressive marketing by pharma companies are
driving the global overactive bladder treatment market. Behavioral
intervention is the first choice in the treatment of overactive bladder
and it is commonly used among patients worldwide. Favorable
reimbursements, innovative treatments, robust pipeline of drugs, and
patent cliff of certain drugs are likely to provide immense growth
opportunities to the overactive bladder treatment market during the
forecast period. However, undesired systemic effects of the current
overactive bladder treatment and side-effect of drugs are likely to be
major restraints of the overactive bladder treatment market during the
forecast period.
The global overactive bladder treatment
market can be segmented based on drug type, disease type, distribution
channel, and region. Based on drug type, the market has been classified
into anticholinergics, mirabegron, Botox, and others. The
anticholinergics segment has been sub-segmented to darifenacin,
oxybutynin, fesoterodine, solifenacin, trospium, and others. In terms of
disease type, the market has been divided into idiopathic overactive
bladder and neurogenic overactive bladder. Idiopathic overactive bladder
is a rapidly expanding segment, owing to increase in the prevalence of
chronic kidney disease (CKD). Rise in elderly population is a major
factor likely to fuel the idiopathic overactive bladder segment in the
near future. In terms of distribution channel, the market can be
segregated into research & hospital pharmacies, retail pharmacies,
independent pharmacies, and others. Geographically, the global
overactive bladder treatment market can be segmented into North America,
Europe, Asia Pacific, and Rest of World.
Among regions, North America dominates
the global overactive bladder treatment market, due to rising geriatric
population suffering from urinary disorders, growing number of devices
receiving regulatory approvals, increasing number of drugs receiving the
FDA approval, and rising demand for new and advanced drugs for clinical
tests in the region. Rising incidence of chronic kidney disease (CKD)
and increasing early-stage diagnosis of diabetes and treatment of other
liver diseases are driving the pharmaceutical industry in North America.
This, in turn, is expected to boost the overactive bladder treatment
market in North America during the forecast period. Europe is the
second-largest market for overactive bladder treatment, due to presence
of favorable government policies regarding development of health care
infrastructure in the region. Expansion of research and development
units and pathology labs in countries of Europe is also a major factor
expected to drive the market in the region during the forecast period.
The market in Asia Pacific is expected to expand at a high growth rate
during the forecast period, due to increase in geriatric population in
the region. Increasing awareness among patients about kidney diseases
and overactive urinary bladder and rising per capita health care
expenditure are factors fueling the market in Asia Pacific.
Additionally, economic growth of India and China is supporting the
development of health care infrastructure as well as expansion of
pharmaceutical companies and biotech labs in these countries. This
factor is also likely to drive the overactive bladder treatment market
in Asia Pacific during the forecast period.
Major players operating in the global
overactive bladder treatment market are Astellas Pharma, Inc., Allergan,
Plc, Aurobindo Pharma Limited, Pfizer, Inc., Teva Pharmaceutical
Industries Limited, Medtronic plc, Mylan N.V., Endo International plc,
and Hisamitsu Pharmaceutical Co., Inc.
No comments:
Post a Comment